Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Cash from Operations: 2022-2023

Historic Cash from Operations for Therapeutics (LENZ) over the last 2 years, with Dec 2023 value amounting to -$21.0 million.

  • Therapeutics' Cash from Operations rose 6.50% to -$21.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$60.4 million, marking a year-over-year increase of 31.37%. This contributed to the annual value of -$59.4 million for FY2024, which is 1.64% up from last year.
  • As of Q4 2023, Therapeutics' Cash from Operations stood at -$21.0 million, which was down 60.22% from -$13.1 million recorded in Q3 2023.
  • Therapeutics' Cash from Operations' 5-year high stood at -$12.8 million during Q1 2023, with a 5-year trough of -$22.4 million in Q4 2022.
  • For the 2-year period, Therapeutics' Cash from Operations averaged around -$18.5 million, with its median value being -$21.1 million (2022).
  • Data for Therapeutics' Cash from Operations shows a peak YoY soared of 41.09% (in 2023) over the last 5 years.
  • Therapeutics' Cash from Operations (Quarterly) stood at -$22.4 million in 2022, then increased by 6.50% to -$21.0 million in 2023.
  • Its Cash from Operations was -$21.0 million in Q4 2023, compared to -$13.1 million in Q3 2023 and -$13.5 million in Q2 2023.